Could Stem Cell-Derived Therapy Open a New Chapter in hEDS Treatment?

An encouraging 2026 study explores a new direction for hypermobile Ehlers-Danlos syndrome research, investigating whether biological treatments could help address some of the processes contributing to hEDS symptoms.
For years, much of the conversation around hypermobile Ehlers-Danlos syndrome (hEDS) has focused on getting a diagnosis, understanding symptoms, and learning how to manage everyday life. For people living with chronic pain, fatigue, joint instability, and the many other challenges associated with hEDS, these areas of care are essential. But alongside them, there is another important question: can we develop treatments that influence the biological processes contributing to these symptoms?
A study published in September 2026 in Frontiers in Medicine takes an encouraging step in that direction. Researchers investigated an experimental treatment made from substances released by stem cells, and six out of ten participants experienced substantial improvements in their symptoms. One participant who received extended treatment remained in apparent symptom remission for 32 months after their final infusion, and no treatment-related adverse events were reported among the ten participants.
These early findings offer an encouraging glimpse into a future where hEDS research explores biological treatments alongside improvements in diagnosis, rehabilitation, and symptom management.
What exactly was the stem cell-derived treatment?
The researchers investigated a treatment called an extracellular vesicle-enriched stem cell secretome. Although the name sounds complicated, the process becomes easier to understand when we look at where the treatment came from and how it was prepared.
1. It started with donated stem cells
The treatment was produced using mesenchymal stem cells derived from human bone marrow. These cells came from donors rather than from the participants themselves, which researchers describe as an allogeneic source.
Mesenchymal stem cells release a wide range of substances that can influence how other cells communicate and behave. Researchers are interested in these substances because of their potential effects on immune regulation, inflammation, and tissue maintenance.
2. Researchers collected what the cells released
The donor stem cells were grown in a controlled laboratory environment, where they released proteins, signalling molecules, lipids, and tiny particles called extracellular vesicles. This mixture of substances is known as the secretome.
Researchers collected, processed, and sterilised the mixture to create the investigational treatment, which participants received through intravenous infusions. The treatment contained substances released by stem cells, rather than living stem cells themselves.
3. Extracellular vesicles help cells communicate
Extracellular vesicles are tiny particles that cells naturally release. They can carry proteins, RNA, and other biological molecules between cells, helping them communicate and influence one another's activity.
You can think of them as small packages carrying biological messages. The treatment contained these vesicles alongside many other substances released by the donor stem cells, with the researchers describing more than 1,000 biologically active molecular species in the preparation.
The researchers wanted to investigate whether this combination of substances could influence biological processes associated with hEDS and improve symptoms.
How might this treatment work in hEDS?
hEDS is a connective tissue disorder, but researchers are increasingly interested in biological processes beyond the structural properties of collagen and ligaments. These include immune regulation, inflammation, cellular communication, and extracellular matrix activity.
The stem cell-derived preparation contains substances that may influence several of these processes, making them possible explanations for the improvements observed in some participants.
Immune regulation and cellular communication
Our immune system constantly communicates with other tissues, influencing inflammation, pain, and how the body responds to stress and injury. The researchers discuss the possibility that substances in the treatment could regulate certain immune-related pathways, particularly because other research has identified differences in immune-associated proteins in people with hEDS.
Extracellular vesicles may contribute to these effects by transporting biological signals between cells. The authors also discuss pathways potentially relevant to mast cell activation, which is associated with symptoms experienced by some people with hEDS.
Understanding which signalling molecules contribute to treatment responses could help researchers identify biological processes involved in the condition and explain why some people respond differently from others.
The extracellular matrix
The extracellular matrix is the network of collagen, elastin, and other molecules that surrounds and supports our cells. It contributes to the structure and function of connective tissues, including ligaments, tendons, and fascia.
The researchers discuss possible effects on extracellular matrix regulation, highlighting proteins such as fibronectin, periostin, and collagen, alongside substances such as hyaluronic acid. These components are involved in connective tissue organisation and cellular communication.
The study assessed changes in symptoms rather than directly measuring tissue structure. Future research could investigate whether the reported improvements are associated with measurable changes in connective tissue biology or immune regulation.
What happened during the study?
The study included ten adults diagnosed with hEDS who received intravenous infusions over approximately five months. Researchers monitored several symptoms and aspects of everyday life, while participants were advised to continue their existing pain-management approaches and medications.
The symptoms assessed included:
Joint pain and looseness, including difficulties associated with instability
Fatigue and overall wellbeing
Brain fog, headaches, and concentration difficulties
Gastrointestinal symptoms
Pain medication use
Six out of ten participants experienced substantial improvements
Six participants reported substantial improvements during treatment, with some noticing changes within one to two weeks of their first infusion. These included reductions in joint pain and fatigue, better concentration, and improvements in overall wellbeing. Some participants also reported reducing their use of pain medication.
The researchers found statistically significant improvements in several symptom measures across the group. However, responses varied, with six individuals showing particularly clear and sustained benefits during the study.
For people living with hEDS, improvements across several symptoms can make a considerable difference to everyday life. Pain, fatigue, and difficulties with concentration often affect one another, so changes in these areas may create more opportunities to move, work, and participate in activities.
What happened when treatment stopped?
Some participants began experiencing a return of symptoms approximately 10 to 12 weeks after an infusion, which led researchers to explore whether repeated treatment could help maintain the improvements.
Among the six participants who responded substantially, five eventually returned to their previous symptom levels after treatment was discontinued. This raises questions about treatment frequency and duration, particularly whether longer treatment could produce more sustained benefits.
What did the researchers observe about safety?
No adverse events of any grade were reported or detected among the ten participants during the study. This is an encouraging early observation, particularly for an experimental treatment involving repeated intravenous infusions.
Larger studies with longer follow-up periods will help researchers understand its safety across a wider population and with different dosing schedules.
One participant experienced a remarkable long-term outcome
One participant who responded particularly well to the initial treatment received approval to continue receiving infusions beyond the original study period. Over 16 months, this participant received nine infusions, allowing researchers to observe their response to a longer treatment schedule.
After the final infusion, the participant continued to experience substantial improvement. According to the researchers, 32 months later, they remained in apparent remission, without recurrence of the symptoms measured in the study. They were also walking three to four miles every other morning without pain, an activity that had previously been impossible.
The researchers described this outcome as an apparent remission. The sustained improvements raise an interesting question about whether extended treatment could produce longer-lasting benefits in certain people, something future studies will need to investigate.
The main findings at a glance
6 out of 10 participants experienced substantial improvements across several hEDS symptoms.
5 of the 6 responders experienced a return of their previous symptoms after treatment stopped.
1 participant receiving extended treatment remained in apparent symptom remission for 32 months after their final infusion.
No adverse events were reported or detected among the ten participants.
Why did some participants improve more than others?
One of the most interesting aspects of the study is the variation between participants' responses. Six experienced substantial improvements, while the other four showed more limited or inconsistent benefits.
This is particularly relevant because hEDS is a highly heterogeneous condition. Two people may share the same diagnosis while experiencing very different combinations of joint instability, pain, fatigue, autonomic symptoms, gastrointestinal difficulties, and other associated conditions.
These differences raise the possibility that similar symptoms may arise from different combinations of underlying biological mechanisms. The researchers discuss this idea because the molecular basis of hEDS remains incompletely understood, and people who meet the same clinical diagnostic criteria may not necessarily share exactly the same biological processes.
If future studies can identify what distinguishes people who respond to a particular treatment from those who do not, researchers may eventually be able to develop more targeted and individualised approaches.
Why this research matters
Much of the practical focus in hEDS has traditionally been on understanding the condition and helping people manage its consequences. Strength development, proprioception, joint control, pacing, pain management, and adapting everyday activities can all play an important role in improving function and quality of life.
At the same time, people living with hEDS deserve research that investigates new medical treatments. This study is particularly meaningful because it explores whether biological processes associated with the condition can be influenced therapeutically.
That opens up possibilities beyond this particular preparation. Even if future research leads toward different treatments, investigating immune regulation, cellular signalling, and the biological differences between patients could help scientists better understand hEDS and develop more individualised care.
What happens next?
The next important step is a larger randomised controlled trial. This initial study involved ten participants, without a comparison group, and relied mainly on symptom questionnaires developed for the research. A larger trial would help establish how consistently the improvements occur and how much of the observed change can be attributed to the treatment.
Future research will also need to investigate:
Who benefits most: Identifying characteristics that distinguish people who respond from those who do not.
How the treatment works: Understanding which biological pathways and signalling molecules contribute to improvements.
Treatment frequency and duration: Exploring whether repeated or extended treatment produces longer-lasting benefits.
Changes in connective tissue function: Investigating whether symptom improvements correspond to measurable changes in tissue properties or joint mechanics.
Long-term safety: Evaluating repeated treatment across larger groups and longer follow-up periods.
These investigations could help determine whether this particular preparation has a place in future medical care while providing valuable information about the biology of hEDS.
What does this mean for us today?
This research offers a genuine reason to be hopeful about the future of hEDS treatment. Seeing researchers investigate therapies that could influence the biological processes contributing to symptoms represents a meaningful development for people who have spent years focusing primarily on diagnosis and symptom management.
As science moves in this direction, the work we do to support our bodies remains just as important. Movement therapy, strength development, joint stability, proprioception, and understanding how our bodies respond to physical demands continue to play an essential role in managing hypermobility and supporting everyday function.
These approaches can develop alongside future biological treatments. If emerging therapies eventually help reduce pain, fatigue, or other symptoms, they may create more opportunities for people to move comfortably, develop strength, and participate in activities that previously felt out of reach. At the same time, building physical capacity requires progressive, individualised movement that supports muscle strength, coordination, joint control, and tolerance for activity.
The possibility of better medical treatments and the importance of movement therapy belong in the same conversation. Better symptom control could make rehabilitation more accessible, while movement therapy continues to develop the physical skills and capacity needed for everyday life.
At Paramotion, we believe that people living with hEDS, HSD, hypermobility, and other chronic health conditions deserve access to research, understandable information, and practical support that helps them make informed decisions about their health and movement.
We want to see science advance in every direction, from improving diagnosis and understanding these conditions to developing treatments that could meaningfully improve people's lives. Alongside these developments, we will continue supporting people through education, movement therapy, and individualised strategies that help them strengthen, stabilise, and better understand their bodies.
For people who have spent years learning to live with their symptoms, seeing research investigate new ways to treat the biological processes contributing to them is something worth celebrating. There is still much to discover, and this study gives researchers another promising direction to explore.
Research reference
Flynn, K. J., Ransom, J. T., & McGrath, D. (2026). A trial of exosome rich stem cell secretome as a potential treatment for Hypermobile Ehlers-Danlos Syndrome. Frontiers in Medicine, 13, 1945865.
This article is intended for patient education. The treatment discussed remains experimental, and its effectiveness and long-term safety for hEDS require confirmation in larger clinical trials.




Comments